General Inception, a Palo Alto, CA-based biotech company igniter, acquired Enable Medicine, a Menlo Park, CA-based company which specializes in AI-led data analysis for biological research and drug discovery.
The amount of the deal was not disclosed.
The strategic partnership will give General Inception access to Enable Medicine’s biological data platform, benefiting life science and biopharmaceutical researchers, while Enable Medicine will benefit from General Inception’s drug development expertise and biotech ecosystem.
Led by Aaron Mayer, co-founder and Chief Scientific Officer, Enable Medicine has developed a platform that aims to improve the capabilities of AI to guide novel insights into biology and medicine. The platform empowers the generative biological search, which uses AI models to search maps of disease for novel drug targets and indications. The approach prioritizes indexing high quality multimodal cellular data to enable the research community and pharmaceutical industry to quickly answer complex questions about disease.
Led by Venkat Reddy, President and Chief Scientific Officer, General Inception (GI) is a company builder that partners with scientific founders at the inception of their journey to translate their innovations into transformational companies that address humanity’s grand challenges. Backed by leading venture capital firms Genoa Ventures, Hughes Ventures, Northpond Ventures, OMX Ventures, Paladin Capital Group, and Vertical Venture Partners, GI brings together domain and functional expertise, executive talent, infrastructure and development resources, and capital to ignite, nurture and scale the company journey.
FinSMEs
16/12/2024